<DOC>
	<DOCNO>NCT00250770</DOCNO>
	<brief_summary>The purpose study follow : 1 . To characterize quantify CSF-1 colony-stimulating factor-1 receptor ( CSF-1R ) expression additional tumor specimen , specifically , tumor high grade metastatic site . 2 . To assay use Enzyme-Linked ImmunoSorbent Assay ( ELISA ) sandwich monoclonal antibody methodology , CSF-1 expression peritoneal fluid blood patient endometrial adenocarcinoma . 3 . Using immunohistochemistry , evaluate presence stain CSF-1 CSF-1R additional patient endometrial adenocarcinoma , especially high grade metastatic site . 4 . To determine extent cytokine , specifically CSF-1 , also interleukin-1 ( IL-1 ) , IL-6 , granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , production , endometrial carcinoma cell primary cell culture . 5 . To determine responsiveness epithelial cell estrogen antiestrogen binding , determine CSF-1 production mediate , cell , estrogen receptor binding , alternative pathway intracellular/cell-cell signal transduction . 6 . The ultimate objective experiment characterize CSF-1 expression benign tumor cell order identify step CSF-1 activate signal pathway may represent potential target therapy .</brief_summary>
	<brief_title>Colony-Stimulating Factor-1 ( CSF-1 ) Other Cytokines Human Endometrial Carcinogenesis</brief_title>
	<detailed_description>These experiment , take together , critically determine role CSF-1/ c-fms autocrine , endocrine , paracrine loop progression endometrial adenocarcinoma . If , alteration loop may provide novel medical therapy disease . Additionally , experiment determine predominant cytokine express tumor , help investigator determine role , , cytokine play cancer cell growth proliferation relationship within outside estrogen-mediated pathway .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Carcinogenesis</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>All patient undergo hysterectomy , endometrial cancer , routine surveillance . Patients may receive prior hormonal , cytotoxic chemotherapy , irradiation surgical therapy . Healthy postmenopausal perimenopausal woman . A consent form must sign patient prior study entry . Patients primary uterine corpus tumor . Patients less one gram tumor tissue available procurement .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Corpus Uteri</keyword>
	<keyword>Endometrium</keyword>
	<keyword>Cancer</keyword>
</DOC>